With experience in nearly 100 clinical trials relating to neuropsychiatric medications and 3 FDA New Drug Applications (NDAs) & Supplemental New Drug Application (sNDA), we specialize in consulting for neuropsychiatric  drug development & commercialization 

• Phase 1 to Phase 4

• Develop Clinical Study Reports (CSRs) with safety & efficacy endpoints/ parameters 

• Help biopharma companies to bring innovative, effective and safe therapeutics to patients

• Develop customized & differential commercial strategies for providers and patients' needs.

• Maximize product launches, develop sales & marketing initiatives, identify influencers/early adopters, and create educational/training materials 

​